divislab glp-1 novo nordisk relation A $60 billion industry just found its next growth lever. 💊 With the expiry of a key patent on March 20, 2026, Indian pharma majors are launching generic weight-loss and diabetes drugs Approaches for half-life extension of

Its an excellent option for those who have struggled with weight loss using traditional diet and exercise alone

Exenatide: from the Gila monster to the pharmacy

Y., & Tadi, P

With appropriate preparationincluding obtaining physician letters, researching country-specific restrictions, and using insulated travel casespatients can safely transport these injectable medications abroad

The functionality of GLP-1R/CRE Luciferase Reporter HEK293 Cell Line was validated in dose-response assays using the peptide agonists Glucagon-like peptide 1 (7-37), Exendin-4, Lixisenatide, GLP-1 moiety from dulaglutide, Semaglutide, Tirzepatide and Retatrutide